title: BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
authors.affiliation: Department of Urology, University of Nijmegen, The Netherlands.
authors.forename: W P
authors.initials: WP
authors.lastname: Witjes
authors.forename: P M
authors.initials: PM
authors.lastname: van der Meijden
authors.forename: E P
authors.initials: EP
authors.lastname: Roos
authors.forename: J A
authors.initials: JA
authors.lastname: Witjes
authors.forename: P A
authors.initials: PA
authors.lastname: Steerenberg
authors.forename: W
authors.initials: W
authors.lastname: Doesburg
authors.forename: F M
authors.initials: FM
authors.lastname: Debruyne
mesh_terms: D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000628:therapy*
chemical_list: D001500:BCG Vaccine; D016685:Mitomycin